Lumen Gentium (The Light of Nations), the Vatican II constitution on the Church, marks its 60th anniversary Nov. 21. As a “dogmatic constitution” of an ecumenical council, it is officially one of the ...
Lumen Gentium (Light of the Nations), the Second Vatican Council’s dogmatic constitution on the Church, celebrates its golden anniversary on Nov. 21 and is no less relevant today than when it was ...
As Jazz Pharmaceuticals ($JAZZ) rolls on with an orphan drug deal spree, shareholders of Gentium ($GENT), its latest target, are suing to stop the acquisition, saying ...
Dec 19 (Reuters) - Ireland-based Jazz Pharmaceuticals Plc said it would buy Italian biotech company Gentium S.p.A. for about $1 billion to get access to Defitelio, a drug used for the treatment of a ...
Jazz Pharmaceuticals PLC plans to buy drug maker Gentium SpA for roughly $1 billion in a cash deal aimed at expanding its rare disease drug portfolio. Shares of Jazz jumped nearly 6 percent to $121.50 ...
VILLA GUARDIA, Italy, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (GENT) (the "Company") announced today that, the Company had presented an oral explanation at the European Medicines Agency's ...
Jazz Pharmaceuticals And Gentium S.p.A. Announce Agreement For Jazz Pharmaceuticals To Acquire Gentium For $57.00 Per Share Transaction would add a significant growth product in the European Union and ...
Pope Paul VI presides over a 1963 session of Vatican II. Credit: CNS photo/Catholic Press Photo. The constitution, wrote America associate editor Donald R. Campion, S.J., shortly after its publication ...
Jazz Pharmaceuticals ( JAZZ) has entered into a definitive agreement to acquire biopharma company Gentium ( GENT) for $57.00 per share in cash or $1 billion. The offer price of $57.00 per share ...
Jazz Pharmaceuticals Plc, the maker of the narcolepsy treatment Xyrem, agreed to buy Gentium SpA, a rare-disease drug developer, in a deal valued at $1 billion. Jazz, based in Dublin, will pay $57 a ...
The offer price of $57.00 per share represents a 2.4% premium to Gentium’s closing price of $55.65 per share on Dec 19, 2013. The transaction is expected to close in the first quarter of 2014. Jazz ...
(Reuters) - Ireland-based Jazz Pharmaceuticals Plc said it would buy Italian biotech company Gentium S.p.A. for about $1 billion to get access to its lead product candidate, Defitelio, a drug used for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results